Table 2 Patient’s characteristics at baseline
From: Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
| Â | BNS01 study | BNS02 study | ||
|---|---|---|---|---|
N = 321 (322)a | N = 61 (61) | |||
n | (%) | n | (%) | |
Sex | ||||
 Man | 200 | 62.3 | 28 | 45.9 |
Age | ||||
 Mean [SD] | 45.2 [14.0] | 42.5 [15.2] | ||
Weight | ||||
 Mean [SD] | 62.6 [13.3] | 59.9 [10.8] | ||
Illness duration (year) | ||||
  < 3 | 34 | (10.6) | 15 | (24.6) |
 3 ≤  < 10 | 54 | (16.8) | 16 | (26.3) |
 10 ≤  | 231 | (72.0) | 28 | (45.9) |
 Unknown | 2 | (0.6) | 2 | (3.3) |
Inpatients | 214 | (66.7) | 18 | (29.5) |
Symptomatology at baseline | ||||
 Hallucinations and delusions | 62 | (19.3) | 18 | (29.5) |
 Delusions | 25 | (7.8) | 9 | (14.8) |
 Deficiency of spontaneity and apathy I (e.g., fresh hebephrenic type) | 15 | (4.7) | 2 | (3.3) |
 Deficiency of spontaneity and apathy II (e.g., chronic type, fixed symptom type) | 200 | (62.3) | 24 | (39.3) |
 Neurosis-like state | 8 | (2.5) | 1 | (1.6) |
 Depressive state | 6 | (1.9) | 5 | (8.2) |
 Others | 5 | (1.6) | 2 | (3.3) |
Predominant symptoms at baseline | ||||
 Predominant positive symptoms | 45 | (14.1) | 15 | (24.6) |
 No predominant | 12 | (3.8) | 5 | (8.2) |
 Predominant negative symptoms | 263 | (82.2) | 41 | (67.2) |
Pre-medicated antipsychotics | ||||
 Yes | 318 | (99.1) | 57 | (93.8) |
Pre-medicated antiparkinsonian | ||||
 Yes | 297 | (92.5) | 56 | (91.8) |
PANSS total at baseline | ||||
 Mean [SD] | 79.5 [24.5] | 69.8 [22.2] | ||